![]() Fishman had responsibility for finance and administration, portfolio optimization, manufacturing, strategy and business development. Fishman served in a leadership role at MedPointe Healthcare, Inc., a private equity backed specialty pharmaceutical company and became the Chief Financial Officer in 2006. Fishman served as Chief Financial Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus company from 2008 to 2010. Fishman also led the negotiation and sale of the company to Actavis plc. While at Durata, he raised substantial capital, including a successful IPO and secondary public offering. overseeing all aspects of finance and administration, manufacturing, business development, strategy, international operations and portfolio optimization. Fishman served as Chief Financial and Chief Operating Officer of Durata Therapeutics, Inc. He completed his internal medicine residency and fellowships in infectious diseases and pulmonary medicine at Yale University School of Medicine.Ĭorey Fishman has served as Chief Executive Officer since late 2015 when the company was formed. Dunne holds a BA in Economics from Northwestern University and an MD from the State University of New York Health Sciences Center. Dunne also served as a member of the board of directors of Aviragen Therapeutics, Inc, a biotechnology company from 2015 to 2018. Dunne served in a variety of roles in connection with the clinical development of numerous infectious disease compounds at Pfizer Inc., including as the Vice President, Therapeutic Head of Development for Infectious Disease from 2001 to 2009. from 2009 until its acquisition by Actavis plc in 2014 and remained in a leadership role as part of the Actavis integration efforts to ensure successful transition of all priority development activities until 2015. Dunne was the Chief Medical Officer of Durata Therapeutics, Inc. Dunne served as the chief scientific officer of Iterum Therapeutics. Dunne currently serves as the chief medical officer at the Gates Medical Research Institute. Hunt is a graduate of The Wharton School (MBA) and Cornell University (BS).ĭr. Hunt held a number of sales and marketing positions for a combined eight years with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Prior to entering the consulting field, Mr. ![]() ![]() His consulting work spanned 4 years and focused on strategic and operational engagements for clients in the pharmaceutical and medical device industries. Hunt was a consultant with the pharmaceutical industry practice at Coopers & Lybrand Consulting and then with The Health Care Group (a division of the Interpublic Group of companies). Prior to joining Sprout in early 1998, Mr. (acquired by Biogen Idec), Aspreva Pharmaceuticals (Nasdaq: ASPV, acquired by Galenica, Inc.), Phase Forward (Nasdaq: PFWD, acquired by Oracle), and Pathology Partners (acquired by Caris Group). (Nasdaq: STIM), Durata Therapeutics (Nasdaq: DRTX, acquired by Actavis), Relypsa (Nasdaq: RLYP), Cerexa (acquired by Forest Laboratories), Stromedix, Inc. Hunt was previously on the boards of Neuronetics, Inc. Hunt is currently on the boards of Rallybio Holdings LLC and Harpoon Therapeutics Inc., and serves as director on the boards of a number of private companies. Hunt has played a significant role in many of the firm’s investments in biopharmaceuticals and in other sectors. Hunt was one of the founders of New Leaf following the spin out from the Sprout Group in 2005, and today has nearly 2 decades of venture capital investment experience. Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on investments in biopharmaceutical companies.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |